Parkinson's Disease Clinical Trial
Official title:
Evaluating Cortical Physiology Following Unilateral and Bilateral Subthalamic Deep Brain Stimulation in Parkinson's Disease
The purpose of this study is to examine the brain changes in people with Parkinson's Disease (PD) after they get deep brain stimulation (DBS) surgery, compared with people who do not have Parkinson's Disease. Treatment of Parkinson's disease is often difficult and challenging. Deep brain stimulation is an established surgical treatment that is effective for the treatment of PD, but the details of why it helps are not known. In order to achieve maximum benefits from this treatment, it is important to understand how it changes the brain. Specifically, the investigators will study electrophysiology, which is the study of how the brain conducts electrical messages to the rest of the body. To do this, the investigators will use transcranial magnetic stimulation (TMS), which is a painless and non-invasive procedure. They will also conduct motor physiology experiments of the upper and lower limbs to collect data about skeletal muscle movement. The data from this study will help explain whether the electrical changes in the brain have any relation to the physical benefits patients with Parkinson's Disease sometimes receive from DBS surgery.
Screening evaluation: The Investigators will ask questions to see if the participant
qualifies to be in the study. The screening visit will occur up to 4 months before the first
study visit, and can be scheduled to occur on the same day as the first study visit. This
evaluation will include a review of medical history and clinical findings related to
Parkinson's Disease (if applicable). There may be a neurological exam (physical exam). Women
of child bearing potential will take a urine pregnancy test. If applicable, the medications
currently used to treat Parkinson's Disease symptoms will be reviewed and subjects will be
asked to discontinue them for some hours on the days of the study visits. The investigators
do not expect concerns or unwanted consequences arising either from discontinuing the
Parkinson's Disease medications or turning off the DBS stimulator for the duration of time
proposed in the study.
Participants will be studied under 4 conditions, over a span of as few as two days to as long
as two months. The four Conditions are : 1) The DBS stimulator will be turned OFF for both
sides. 2) The DBS stimulator will be turned ON for the right side. 3) The DBS stimulator will
be turned ON for the left side. 4) The DBS stimulator will be turned ON for both sides. The
order of these conditions will be picked randomly.
Participants will be asked not to take PD medications for approximately 12 hours prior to the
scheduled visit time, and until after the physiological testing.
Healthy controls will be studied on only one occasion, as they do not have DBS.
Tests performed for each study condition:
1. Parkinson's Participants Only: A neurological examination will be performed by
administering several clinical scaled. These clinical scales include the Unified
Parkinson's Disease Rating Scale (UPDRS), the self-report Parkinson's Disease Quality of
life scale (PDQ-39), MMSE instrument for cognitive (or memory) testing, and Beck
Depression Inventory (BDI II) for evaluation of mood and depressive symptoms. The
PDQ-39, MMSE, and BDI will each only be administered once and therefore will not be
repeated at every study visit.
2. The investigators will determine individual motor evoked potential (MEP) thresholds
before beginning the study treatment. MEP will be recorded from a muscle located between
the right thumb and index finger, and then from the left thumb and index finger. MEP
threshold refers to the amount of stimulation to the brain that is required to activate
muscle cells enough to appear on an electromyography (EMG), which records electrical
potential in muscle through electrodes placed on the skin.
3. The investigators will use TMS to test motor cortex functions. For these tests,
participants will sit in a chair that looks like the one at the dentist's office. A
magnetic coil will be placed on the scalp on one side of the head, overlying the brain's
motor cortex to stimulate the brain's output to the muscles in the opposite hand. A
second magnetic coil will be placed on the scalp of opposite side. Recordings from both
hands will be made using the magnetic coils placed on scalp.
4. The investigators will collect data about the muscles of both the upper and lower limbs
with a wireless EMG procedure. To do this, small wireless sensors will be placed on the
skin over both arm and leg muscles. Participants will be asked to sit in a chair and
perform movements with the upper and lower limbs while the EMG records measurements
about movement activity. This procedure will be conducted separately for the upper and
lower limbs.
5. Participants who have provided consent will be videotaped during the visits.
6. Side effects and adverse events pertaining to this study will be recorded at each visit.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |